Adverse effects of benzodiazepines limit their clinical use; these effects might be reduced without altering therapeutic effects by administering other positive GABA A modulators (i.e., neuroactive steroids) with benzodiazepines. One concern with this strategy involves reversing these combined effects in case of overdose. The current study examined whether flumazenil can additive. Flumazenil antagonized the benzodiazepines when they were administered alone or in combination. Schild analyses yielded slopes that did not deviate from unity, regardless of whether benzodiazepines were administered alone or together; the pA 2 value for flumazenil was 7.58. In contrast, flumazenil enhanced the effects of pregnanolone with 0.32 mg/kg flumazenil shifting the pregnanolone dose-effect curve 2-fold leftward. Flumazenil attenuated the combined effects of midazolam and pregnanolone, although antagonism was not dose dependent. Thus, the interaction between two benzodiazepines was similar to that of a benzodiazepine and a neuroactive steroid; however, flumazenil more efficiently attenuated a combination of two benzodiazepines, as compared with a combination of a benzodiazepine and a neuroactive steroid.
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Introduction
Benzodiazepines have been widely used to treat anxiety, insomnia, convulsions and ethanol withdrawal. While they are safe and effective, long-term use has revealed adverse effects, particularly tolerance and dependence. One strategy that might retain the therapeutic effects of benzodiazepines while reducing adverse effects is to develop other positive modulators of γ -aminobutyric acid A (GABA A ) receptors, such as neuroactive steroids. Although benzodiazepines and neuroactive steroids act at distinct sites on GABA A receptors, they both facilitate the actions of GABA, thereby increasing Cl -flux and producing similar acute behavioral effects. Like benzodiazepines, neuroactive steroids have anxiolytic (Wieland et al., 1997) , sedative (Lancel, 1999; Vanover et al., 1999) and anticonvulsant effects (Gasior et al., 2000; Kokate et al., 1994; Reddy and Rogawski, 2001 ) and can reverse ethanol withdrawal (Finn et al., 2000) . Despite these similarities, the effects of neuroactive steroids and benzodiazepines are not identical with differences emerging during chronic treatment; for example, tolerance and dependence are less likely to develop during chronic treatment with neuroactive steroids, as compared with benzodiazepines (Eppolito and Gerak, 2010; Kokate et al., 1998; Reddy and Rogawski, 2000) . Although the ramifications of long-term therapeutic use of neuroactive steroids are not known, lack of tolerance could provide a clinical advantage for neuroactive steroids over benzodiazepines. In contrast, there are other factors that might make the therapeutic use of benzodiazepines more appealing than that of neuroactive steroids, such as the availability of a pharmacological antagonist (e.g., flumazenil), which can reverse effects of benzodiazepines in the event of overdose; no such compound is available to reverse the effects of One way to combine the benefits of benzodiazepines and neuroactive steroids might be to administer them concurrently. Drug combinations have been used successfully to treat other conditions. For example, when drugs (e.g., opioids and nonsteroidal anti-inflammatory drugs)
are given together to relieve pain, smaller doses of each drug are needed to produce the desired effect; those smaller doses along with actions through different mechanisms reduce adverse effects. A similar approach might be used with positive modulators acting at different sites on GABA A receptors to retain positive aspects of each drug while reducing less desirable features.
Studies in monkeys suggest that combinations of benzodiazepines and neuroactive steroids might provide clinical advantages by retaining therapeutic effects while reducing adverse effects. For example, combinations of the benzodiazepine triazolam and the neuroactive steroid pregnanolone produced supra-additive effects in a conflict procedure, which provides a measure of anxiolytic effects (Fischer and Rowlett, 2011) . When discriminative stimulus effects or rates of lever pressing were measured, the interaction was additive (McMahon and France, 2005; Fischer and Rowlett, 2011) , and in monkeys self administering a combination of triazolam and pregnanolone, the interaction was either additive or infra-additive, depending on the ratio of doses used (Fischer and Rowlett, 2011) . Thus, the combined effects of positive GABA A modulators can vary, enhancing some effects more than others.
Although benzodiazepines are generally safe, severe respiratory depression can occur when benzodiazepines are given with other drugs (e.g., ethanol), and toxicity can be reduced with flumazenil, which reverses the benzodiazepine component of the mixture. Flumazenil
This article has not been copyedited and formatted. The final version may differ from this version. (Lelas et al., 1999; McMahon et al., 2002) ; however, it enhances the effects of neuroactive steroids, shifting dose-effect curves leftward (McMahon and France, 2005; Gerak and France, 2011) , which reflects the positive efficacy of flumazenil (Dantzer and Pério, 1982) . Thus, flumazenil could enhance or attenuate the combined effects of benzodiazepines and neuroactive steroids depending on the proportion of each drug in the mixture.
This study examined the ability of flumazenil to alter the effects of pregnanolone, midazolam and another benzodiazepine flunitrazepam, given alone or together. Drug combinations were administered using a fixed-ratio design such that the proportion remained constant based on the potency of each drug to produce midazolam-lever responding. According to receptor theory, flumazenil should attenuate the effects of all benzodiazepines, regardless of whether they are administered alone or together. These studies tested that hypothesis by comparing the combined effects of two benzodiazepines to the combined effects of a benzodiazepine and a neuroactive steroid and determining the extent to which flumazenil attenuates each drug combination.
This article has not been copyedited and formatted. The final version may differ from this version. water while in their home cages. They were trained to discriminate midazolam at least one year before the start of these studies (Gerak and France, 2011) . Three monkeys (subjects SA, LI, and NI) contributed to all data presented. A fourth monkey (subject RO) participated in studies in which 1) midazolam was given alone and with flumazenil, 2) flunitrazepam was given alone, and
3) a mixture of midazolam and flunitrazepam was administered with and without flumazenil.
That monkey was replaced by a fifth monkey (subject HE) who participated in studies in which 1) midazolam was studied alone, 2) pregnanolone was given alone and with flumazenil, and 3) a mixture of midazolam and pregnanolone was administered with and without flumazenil.
Monkeys used in these studies were maintained in accordance with the Institutional Animal Care when the following criteria were satisfied: ≥80% responding on the injection-appropriate lever during each cycle and fewer than 10 responses on the incorrect lever prior to completion of the first fixed ratio on the correct lever. Before their first test session, monkeys satisfied these criteria for five consecutive or six of seven training sessions; thereafter, test sessions were conducted when these criteria were satisfied for two consecutive training sessions. When monkeys did not satisfy the testing criteria, training continued until the criteria were satisfied during two consecutive sessions.
Test sessions were identical to training sessions except that 10 consecutive responses on either lever postponed shock and various doses of test compounds were administered during the first minute of each cycle. Dose-effect curves for midazolam, flunitrazepam and pregnanolone were generated by administering vehicle on the first cycle and test compound during subsequent cycles with the cumulative dose increasing by ¼ log unit per cycle. Dosing continued until monkeys responded ≥ 80% on the midazolam lever. From these dose-effect curves, the dose needed to produce 50% responding on the drug lever ( ED 50 values were estimated by fitting straight lines to individual dose-effect curves for each monkey; each line was estimated by linear regression using one dose that produced not more than 25% responding on the drug lever, one dose that produced at least 75% responding on the drug lever, and all doses in between. Potency ratios were calculated for each animal by either 1 or 2 benzodiazepines, dose ratios were also used to construct Schild plots. Using the method of Arunlakshana and Schild (1959) , log (dose ratio-1) was determined for individual monkeys, averaged, and plotted as a function of flumazenil dose (-log [mol/kg]). Straight lines were fitted to each Schild plot using GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego, CA) and the following equation: log (dose ratio-1) = -log(molar dose of flumazenil)*slope + intercept. Schild plots generated using midazolam and flunitrazepam either alone or in combination were compared using an F-ratio test (Kenakin, 1993; Koek et al., 2000) .
The slope of the Schild plot was constrained to unity in the simpler model and allowed to vary in the more complex model. If the calculated F value was not significant, then the data were best fit by the simpler model (i.e., slope constrained to -1). When slopes of Schild plots were constrained to unity, apparent pA 2 values were compared using an F-ratio test. When slopes were not constrained, apparent pA 2 values (95% CI) were determined using linear regression of Schild plots. Significance was set at P<0.05.
This article has not been copyedited and formatted. The final version may differ from this version. common slope constrained to unity, the apparent pA 2 value was 7.58. When the three Schild plots were analyzed independently, the unconstrained slope of each line was not significantly different from unity yielding apparent pA 2 values that were also not significantly different (Table   1) .
Although flumazenil antagonized the discriminative stimulus effects of benzodiazepines, it enhanced the discriminative stimulus effects of pregnanolone, shifting the pregnanolone dose- regardless of which modulatory site mediates those effects. One way that actions at different sites can be detected is to study high-efficacy drugs with a low-efficacy drug that acts at one of the two sites (e.g., flumazenil). Under these conditions, flumazenil is expected to attenuate the effects of drugs acting at the same (e.g., benzodiazepine) site and should not alter the effects of drugs acting at different sites. Flumazenil enhances the discriminative stimulus effects of pregnanolone, shifting its dose-effect curve leftward and confirming that flumazenil has some positive efficacy (Dantzer and Pério, 1982) . One possible strategy for retaining the therapeutic effects of benzodiazepines while reducing their adverse effects is to administer benzodiazepines and neuroactive steroids together.
This strategy would allow smaller doses of each drug to be used, which might decrease adverse effects, such as the development of tolerance. The consequences of repeated daily treatment are different for benzodiazepines, as compared with neuroactive steroids. During chronic benzodiazepine treatment, tolerance develops readily to many effects of benzodiazepines, including decreases in lever pressing (McMahon and France, 2002b) and anticonvulsant effects (Gonsalves and Gallagher, 1987; Löscher et al., 1996) , although cross tolerance does not develop to decreases in lever pressing produced by neuroactive steroids (Gerak, 2009) either drug that would be needed when administered alone, might decrease the likelihood of tolerance and cross tolerance developing. In addition, the proportion of each drug in the mixture might be titrated to optimize the therapeutic effects while minimizing the possibility that tolerance develops.
Unlike the development of tolerance and dependence, some undesired effects are common among positive modulators, regardless of the binding site that mediates their effects, and would be expected to occur when they are administered in combination. For example, positive modulators decrease ventilation and they can produce severe respiratory depression when administered together (e.g., benzodiazepines and ethanol). While these effects will only occur when large doses are administered concurrently, it is important to know whether the effects could be reversed in case of overdose. In the current study, flumazenil antagonizes the effects of a benzodiazepine given alone and with another benzodiazepine. Although flumazenil enhances the effects of pregnanolone administered alone, it does not enhance the effects of a combination of midazolam and pregnanolone and modestly attenuates their combined effects at a dose of 0.32 mg/kg. It is not clear whether a combination of benzodiazepines and neuroactive steroids would produce life-threatening adverse effects; however, flumazenil might be useful in reducing toxicity caused by the combination. Moreover, because one component of the mixture, the neuroactive steroid, will be resistant to antagonism by flumazenil, the proportion of each component in the mixture could be adjusted to obtain the most ideal combination of a benzodiazepine and a neuroactive steroid; this proportion would decrease the likelihood that tolerance and dependence develop to the mixture while retaining the ability to attenuate the effects in case of overdose.
This article has not been copyedited and formatted. The final version may differ from this version. The generality of these findings to other dependent variables needs to be determined empirically; however, drug discrimination seems to be predictive of effects across a wide range of conditions. For example, many, if not all, effects of benzodiazepines are mediated by benzodiazepine sites on GABA A receptors, including their discriminative stimulus, therapeutic and adverse effects. While absolute potency of drugs acting at benzodiazepine sites can vary across procedures, relative potencies do not change (Lelas et al., 1999; Rowlett et al., 2006) .
Drug discrimination has been used extensively to examine interactions between GABA A modulators that vary in efficacy and site of action on GABA A receptors (current study; Lelas et al., 2000; McMahon and France, 2005; Gerak and France, 2011) , providing an empirical and theoretical framework against which results could be compared and demonstrating that drug discrimination studies are highly reliable and predictable. Finally, under the conditions used in the current study, additive interactions have been observed between positive modulators acting at different sites, and flumazenil has been shown to enhance the effects of pregnanolone, providing a baseline against which the relative enhancement or attenuation of the combined effects of positive modulators can be compared. Consequently, there appears to be little evidence to suggest that results would be different with other dependent variables and a number of reasons to believe that the discriminative stimulus effects of positive GABA A modulators will be predictive of other effects.
In summary, the ability of flumazenil to antagonize benzodiazepines administered concurrently could not be distinguished from its ability to antagonize a single benzodiazepine. and pregnanolone been studied (Fischer and Rowlett, 2011) , the data obtained to date support the view that combinations of benzodiazepines and neuroactive steroids could be useful in retaining the therapeutic effects of benzodiazepines and reducing their individual adverse effects while at least partially retaining the ability to reverse accidental overdose.
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